| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $34.5M | — | +27.9% |
| SG&A Expense | $12.5M | — | +69.9% |
| Operating Income | -$46.5M | — | -40.3% |
| Net Income | -$40.8M | — | -38.4% |
| EPS (Basic) | -$0.85 | — | -3.7% |
| EPS (Diluted) | -$0.85 | — | -3.7% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $627.7M | +1128.6% | +6104.7% |
| Short-term Investments | $483.6M | +36.9% | +91.1% |
| Accounts Receivable | $1.2M | +2265.4% | +23.0% |
| Current Assets | $1.12B | +173.5% | +313.3% |
| Total Assets | $1.25B | +134.9% | +257.7% |
| Current Liabilities | $38.3M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$28.9M | — | -4.4% |
| Capital Expenditures | $10K | — | -58.3% |
| Investing Cash Flow | -$134.0M | — | -1005.6% |
| Financing Cash Flow | $739.4M | — | — |
| Free Cash Flow | -$28.9M | — | -4.4% |
| +125.8% |
| Total Liabilities | $45.6M | +21.5% | +128.1% |
| Stockholders' Equity | $1.20B | +143.5% | +265.6% |